MAP
PNT

Moody Aldrich Partners’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Moody Aldrich Partners’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-145,442
Closed -$1.32M – 220
2023
Q2 		$1.32M Buy
+145,442
New +$1.28M 0.26% 108

Other funds holding PNT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Moody Aldrich Partners's PNT Position: Q3 2023 in Review

Moody Aldrich Partners sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q3 2023, closing a stake of 145,442 shares — an estimated $1.32M sold.

Moody Aldrich Partners first reported a position in PNT in Q2 2023 and held it in 1 quarter. The position peaked at $1.32M in Q2 2023. 125 funds tracked by Wall St. Rank hold PNT as of Q3 2023.

  • Moody Aldrich Partners reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Moody Aldrich Partners sold 145,442 POINT Biopharma Global Inc. Common Stock shares in Q3 2023, an estimated $1.32M.
  • Moody Aldrich Partners first reported a position in POINT Biopharma Global Inc. Common Stock in Q2 2023 and held it in 1 quarter.
  • Moody Aldrich Partners's POINT Biopharma Global Inc. Common Stock position peaked at $1.32M in Q2 2023.
  • 125 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q3 2023.

Based on Moody Aldrich Partners's 13F filing for Q3 2023, filed 8 Nov 2023.